[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![US_ShipOfState Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::986403517081505793.png) US Ship of State [@US_ShipOfState](/creator/twitter/US_ShipOfState) on x 89.6K followers
Created: 2025-07-22 19:30:15 UTC

AstraZeneca, Pfizer and other multinational drug companies have spent a record amount on medicines developed by Chinese biotechs this year.

China has comprised XX per cent of licensing deals globally for multinational companies so far this year, up from XX per cent last year and its largest-ever share. A third of the deal value came from China, also a record.

In these deals, a pharmaceutical company pays a Chinese biotech for exclusive rights to sell an early-stage drug, usually outside China. If the drug advances through trials, the Chinese companies can earn more.

The Trump administration is finalizing unprecedented US tariffs for the global pharmaceutical sector.



![](https://pbs.twimg.com/media/GwfDjcUWMAEn1dX.png)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1947740996395274670/c:line.svg)

**Related Topics**
[cent](/topic/cent)
[china](/topic/china)
[$azn](/topic/$azn)
[stocks healthcare](/topic/stocks-healthcare)
[$pfe](/topic/$pfe)

[Post Link](https://x.com/US_ShipOfState/status/1947740996395274670)